drugset / Trial / NCT00863772

Tanezumab and Nerve Function In Arthritis Patients

NCT00863772

Phase 3 Terminated 220 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.

Timeline

Start
2009-05-18
Primary completion
2010-11-16
Completion
2010-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 5 mg Intravenous
Subject Tanezumab Monoclonal antibody 10 mg Intravenous

Indications